The short answer
Fenugreek has not been shown to change semaglutide absorption or increase hypoglycemia with it. A low-glucose event in a different diabetes regimen warrants caution but does not establish this pair.
What this answer covers
Defined fenugreek capsules versus seed foods, teas and extracts; oral semaglutide and weekly injections differ.
- Supplement or preparation
- Trigonella foenum-graecum
- Medication ingredient
- semaglutide
A small trial used a different regimen
A pilot study compared fenugreek plus metformin with glibenclamide plus metformin. It reported one hypoglycemia event in the fenugreek group, but did not test semaglutide and did not clearly establish a fasting-glucose benefit.
The rest of the diabetes regimen matters
Semaglutide’s insulin and glucagon effects depend on glucose levels. Its labels particularly flag hypoglycemia when insulin or a sulfonylurea is also used. That warning does not establish a hypoglycemia rate for this supplement combination.
Tablet timing differs from injection timing
Take a semaglutide tablet on an empty stomach in the morning with up to 4 ounces of plain water. Wait at least 30 minutes before food, drinks or another oral product, including a supplement. Weekly injections do not have this fasting or 30-minute rule.
Do not transfer another drug’s findings
The small trial cannot measure this pair’s adverse-event rate or show that fenugreek changes semaglutide blood levels. Review the exact preparation and unusual glucose readings with the clinician. Do not change semaglutide or rely on spacing to prevent hypoglycemia.
Evidence and practical considerations
Absorption & effectiveness
No exact-pair clinical evidence establishes the claimed change in semaglutide exposure, effectiveness or safety. Indirect preparation-specific findings and contrary/null results retained; general tablet administration is a separate finding.
- Exact scope
- Defined fenugreek capsules versus seed foods, teas and extracts; oral semaglutide and weekly injections differ. with Semaglutide RxCUI 1991302 IN; exact oral-tablet and subcutaneous formulation boundaries.
- Medication form and route
- oral medication; subcutaneous medication; oral supplement
What remains uncertain
- No supplement-specific percentage, event rate, nutrient requirement or injection gap established.
Factors that may matter: Formulation; Preparation; Insulin or sulfonylurea co-use; Gastrointestinal symptoms.
Read the supporting source summaries
Source 1: current product label
dailymed.nlm.nih.gov · Source check Sep 10, 2026
Population: Patients prescribed the named semaglutide formulation
Glucose-dependent insulin/glucagon effects; hypoglycemia risk with insulin/secretagogues. Gastric-emptying precautions. Oral tablets require fasting morning dosing with up to 4 ounces plain water and at least 30 minutes before other oral medicines, food or drink. Weekly injections can be given with or without meals.
How this applies: Exact named semaglutide formulation; oral and subcutaneous administration distinguished.
No ingredient-specific supplement interaction or routine nutrient need established. Tablet strengths/formulations not automatically interchangeable; injection has no tablet fasting rule.
Source 2: current product label
dailymed.nlm.nih.gov · Source check Sep 10, 2026
Population: Patients prescribed the named semaglutide formulation
Weekly subcutaneous dosing with or without meals. Glucose-dependent effects; hypoglycemia risk with insulin/secretagogues. Gastric emptying delayed but studied oral drugs had no clinically relevant absorption effect.
How this applies: Exact named semaglutide formulation; oral and subcutaneous administration distinguished.
No ingredient-specific supplement interaction or routine nutrient need established. Tablet strengths/formulations not automatically interchangeable; injection has no tablet fasting rule.
Source 3: current product label
dailymed.nlm.nih.gov · Source check Sep 10, 2026
Population: Patients prescribed the named semaglutide formulation
Glucose-dependent insulin/glucagon effects; hypoglycemia risk with insulin/secretagogues. Gastric-emptying precautions. Oral tablets require fasting morning dosing with up to 4 ounces plain water and at least 30 minutes before other oral medicines, food or drink. Weekly injections can be given with or without meals.
How this applies: Exact named semaglutide formulation; oral and subcutaneous administration distinguished.
No ingredient-specific supplement interaction or routine nutrient need established. Tablet strengths/formulations not automatically interchangeable; injection has no tablet fasting rule.
Source 4: original human pharmacokinetic study
pubmed.ncbi.nlm.nih.gov · Source check Sep 10, 2026
Population: 45 healthy participants in two-part study
Co-administration with placebo tablets reduced semaglutide exposure by 34%. Levothyroxine exposure increased in a different comparison.
How this applies: Supports oral administration conditions, not herb-specific pharmacokinetics or clinical harm.
Placebo tablets, not any named supplement. Not injected semaglutide or a proven percentage effect for current different tablet formulations. Abstract only.
Source 5: original human study
pubmed.ncbi.nlm.nih.gov · Source check Sep 10, 2026
Population: Small uncontrolled-diabetes cohort.
Fasting-glucose reduction with fenugreek not significant; one hypoglycemia event reported in fenugreek/metformin arm.
How this applies: Indirect for semaglutide; exact original exposure, preparation and endpoint retained.
Fenugreek plus metformin versus glibenclamide plus metformin, not fenugreek combined with glibenclamide or semaglutide. Small pilot with inconsistent completion wording.
Research assessment: · Open full citations ↗
Side effects & toxicity
No exact-pair clinical evidence establishes the claimed change in semaglutide exposure, effectiveness or safety. Indirect preparation-specific findings and contrary/null results retained; general tablet administration is a separate finding.
- Exact scope
- Defined fenugreek capsules versus seed foods, teas and extracts; oral semaglutide and weekly injections differ. with Semaglutide RxCUI 1991302 IN; exact oral-tablet and subcutaneous formulation boundaries.
- Medication form and route
- oral medication; subcutaneous medication; oral supplement
What remains uncertain
- No supplement-specific percentage, event rate, nutrient requirement or injection gap established.
Factors that may matter: Formulation; Preparation; Insulin or sulfonylurea co-use; Gastrointestinal symptoms.
Read the supporting source summaries
Source 1: current product label
dailymed.nlm.nih.gov · Source check Sep 10, 2026
Population: Patients prescribed the named semaglutide formulation
Glucose-dependent insulin/glucagon effects; hypoglycemia risk with insulin/secretagogues. Gastric-emptying precautions. Oral tablets require fasting morning dosing with up to 4 ounces plain water and at least 30 minutes before other oral medicines, food or drink. Weekly injections can be given with or without meals.
How this applies: Exact named semaglutide formulation; oral and subcutaneous administration distinguished.
No ingredient-specific supplement interaction or routine nutrient need established. Tablet strengths/formulations not automatically interchangeable; injection has no tablet fasting rule.
Source 2: current product label
dailymed.nlm.nih.gov · Source check Sep 10, 2026
Population: Patients prescribed the named semaglutide formulation
Weekly subcutaneous dosing with or without meals. Glucose-dependent effects; hypoglycemia risk with insulin/secretagogues. Gastric emptying delayed but studied oral drugs had no clinically relevant absorption effect.
How this applies: Exact named semaglutide formulation; oral and subcutaneous administration distinguished.
No ingredient-specific supplement interaction or routine nutrient need established. Tablet strengths/formulations not automatically interchangeable; injection has no tablet fasting rule.
Source 3: current product label
dailymed.nlm.nih.gov · Source check Sep 10, 2026
Population: Patients prescribed the named semaglutide formulation
Glucose-dependent insulin/glucagon effects; hypoglycemia risk with insulin/secretagogues. Gastric-emptying precautions. Oral tablets require fasting morning dosing with up to 4 ounces plain water and at least 30 minutes before other oral medicines, food or drink. Weekly injections can be given with or without meals.
How this applies: Exact named semaglutide formulation; oral and subcutaneous administration distinguished.
No ingredient-specific supplement interaction or routine nutrient need established. Tablet strengths/formulations not automatically interchangeable; injection has no tablet fasting rule.
Source 4: original human pharmacokinetic study
pubmed.ncbi.nlm.nih.gov · Source check Sep 10, 2026
Population: 45 healthy participants in two-part study
Co-administration with placebo tablets reduced semaglutide exposure by 34%. Levothyroxine exposure increased in a different comparison.
How this applies: Supports oral administration conditions, not herb-specific pharmacokinetics or clinical harm.
Placebo tablets, not any named supplement. Not injected semaglutide or a proven percentage effect for current different tablet formulations. Abstract only.
Source 5: original human study
pubmed.ncbi.nlm.nih.gov · Source check Sep 10, 2026
Population: Small uncontrolled-diabetes cohort.
Fasting-glucose reduction with fenugreek not significant; one hypoglycemia event reported in fenugreek/metformin arm.
How this applies: Indirect for semaglutide; exact original exposure, preparation and endpoint retained.
Fenugreek plus metformin versus glibenclamide plus metformin, not fenugreek combined with glibenclamide or semaglutide. Small pilot with inconsistent completion wording.
Research assessment: · Open full citations ↗
Timing & monitoring
Oral semaglutide is taken fasting and at least 30 minutes before other oral products; this administration rule does not establish a botanical-specific interaction or apply to weekly injections.
- Exact scope
- Defined fenugreek capsules versus seed foods, teas and extracts; oral semaglutide and weekly injections differ. with Current semaglutide tablets versus injections.
- Medication form and route
- oral medication; oral supplement
What remains uncertain
- Not a protective gap for all pharmacodynamic effects.
Factors that may matter: Formulation.
Read the supporting source summaries
Source 1: current product label
dailymed.nlm.nih.gov · Source check Sep 10, 2026
Population: Patients prescribed the named semaglutide formulation
Glucose-dependent insulin/glucagon effects; hypoglycemia risk with insulin/secretagogues. Gastric-emptying precautions. Oral tablets require fasting morning dosing with up to 4 ounces plain water and at least 30 minutes before other oral medicines, food or drink. Weekly injections can be given with or without meals.
How this applies: Exact named semaglutide formulation; oral and subcutaneous administration distinguished.
No ingredient-specific supplement interaction or routine nutrient need established. Tablet strengths/formulations not automatically interchangeable; injection has no tablet fasting rule.
Source 2: current product label
dailymed.nlm.nih.gov · Source check Sep 10, 2026
Population: Patients prescribed the named semaglutide formulation
Weekly subcutaneous dosing with or without meals. Glucose-dependent effects; hypoglycemia risk with insulin/secretagogues. Gastric emptying delayed but studied oral drugs had no clinically relevant absorption effect.
How this applies: Exact named semaglutide formulation; oral and subcutaneous administration distinguished.
No ingredient-specific supplement interaction or routine nutrient need established. Tablet strengths/formulations not automatically interchangeable; injection has no tablet fasting rule.
Source 3: current product label
dailymed.nlm.nih.gov · Source check Sep 10, 2026
Population: Patients prescribed the named semaglutide formulation
Glucose-dependent insulin/glucagon effects; hypoglycemia risk with insulin/secretagogues. Gastric-emptying precautions. Oral tablets require fasting morning dosing with up to 4 ounces plain water and at least 30 minutes before other oral medicines, food or drink. Weekly injections can be given with or without meals.
How this applies: Exact named semaglutide formulation; oral and subcutaneous administration distinguished.
No ingredient-specific supplement interaction or routine nutrient need established. Tablet strengths/formulations not automatically interchangeable; injection has no tablet fasting rule.
Source 4: original human pharmacokinetic study
pubmed.ncbi.nlm.nih.gov · Source check Sep 10, 2026
Population: 45 healthy participants in two-part study
Co-administration with placebo tablets reduced semaglutide exposure by 34%. Levothyroxine exposure increased in a different comparison.
How this applies: Supports oral administration conditions, not herb-specific pharmacokinetics or clinical harm.
Placebo tablets, not any named supplement. Not injected semaglutide or a proven percentage effect for current different tablet formulations. Abstract only.
Research assessment: · Open full citations ↗
Review and change history
- Publication status
- Published research summary
- Clinical review
- Not yet recorded
| Date | Update |
|---|---|
| Article prepared | |
| Prepared exact semaglutide article distinguishing oral administration, injected treatment and supplement-specific evidence. | |
| Research summary published |
Article revision: 16f24576571c643a
This guide brings together the evidence records used by our interaction checker. Each finding retains its own preparation limits, research date, and source summaries.
Full citations require verification. Reading this answer and the source summaries does not.
Taking other supplements or medications?
Use the checker to explore your other combinations. Ask a pharmacist to review the exact products, amounts and medical conditions in your complete list.
Open the interaction checkerInformation, not medical advice. Do not change prescribed treatment based on this guide.